Inventor
MEHRLING THOMAS JORG
CH19 patents
⚠️ This page may combine multiple inventors who share the name “MEHRLING THOMAS JORG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PURDUE PHARMA LP
9 patentsUS11413276B2Aug 16, 2022
Compounds for treating TNBC
PURDUE PHARMA LP14 citations93
US11318117B2May 3, 2022
Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
PURDUE PHARMA LP15 citations90
US11786509B2Oct 17, 2023
Compounds for treating TNBC
PURDUE PHARMA LP6 citations85
US11576899B2Feb 14, 2023
Tinostamustine for use in treating sarcoma
PURDUE PHARMA LP5 citations85
US11918558B2Mar 5, 2024
Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia
PURDUE PHARMA LP4 citations82
US12303492B2May 20, 2025
Compounds for treating TNBC
PURDUE PHARMA LP0 citations62
US12257237B2Mar 25, 2025
Tinostamustine for use in treating sarcoma
PURDUE PHARMA LP0 citations62
US12370178B2Jul 29, 2025
Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
PURDUE PHARMA LP0 citations59
US12377076B2Aug 5, 2025
Compounds for treating lymphoma or a T-cell malignant disease
PURDUE PHARMA LP0 citations49
PURDUE PHARMACEUTICAL PRODUCTS L P
8 patentsUS11559516B2Jan 24, 2023
Pharmaceutical combinations for treating cancer
PURDUE PHARMACEUTICAL PRODUCTS L P9 citations93
US10406138B2Sep 10, 2019
Pharmaceutical combinations for treating cancer
PURDUE PHARMACEUTICAL PRODUCTS L P20 citations93
US9993482B2Jun 12, 2018
Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer
PURDUE PHARMACEUTICAL PRODUCTS L P23 citations93
US12064417B2Aug 20, 2024
Combination comprising a glucocorticoid and EDO-S101
PURDUE PHARMACEUTICAL PRODUCTS L P5 citations84
US12048688B2Jul 30, 2024
Pharmaceutical combinations for treating cancer
PURDUE PHARMACEUTICAL PRODUCTS L P4 citations84
US11541038B2Jan 3, 2023
Combination comprising a glucocorticoid and EDO-S101
PURDUE PHARMACEUTICAL PRODUCTS L P10 citations84
US12403130B2Sep 2, 2025
Pharmaceutical combinations for treating cancer
PURDUE PHARMACEUTICAL PRODUCTS L P0 citations61
US12370177B2Jul 29, 2025
Compounds for treating brain cancer
PURDUE PHARMACEUTICAL PRODUCTS L P0 citations58